BIO-RAD LABORATORIES, INC. acquired Celsee, Inc. for $99.3 million total consideration, including fair value of contingent consideration of up to $60.0 million payable on certain 2021-2022 net-revenue achievement, a transaction completed in April 2020, structured as all cash plus contingent consideration.
Celsee, Inc. operates in Life Science. Bio-Rad acquired Celsee, an Ann Arbor, Michigan company founded in 2011 that supplies instruments and consumables for isolating, detecting and analyzing single cells for research, translational and biopharma laboratories. Announced in April 2020, the deal extended Bio-Rad's reach into single-cell analysis and precision medicine. Celsee's platform scales from hundreds of thousands to millions of cells for genomic and proteomic work and can enrich circulating tumor cells to help track disease progression and therapeutic response.
We believe this acquisition will complement our Life Science product offerings.
Single-cell isolation and analysis platform adjacent to Bio-Rad's Life Science franchise. Complements Life Science product offerings. Life Science segment
Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings.Bio-Rad Laboratories FY2020 10-K, Acquisitions note
Advisory firms were not disclosed for this transaction.